• MAY 26 2017

    Dr. Joshua Allen to Present Results of ONC201 in Recurrent GBM at the 2017 Brain Tumor Biotech Summit

    Dr. Joshua Allen, VP of Research and Development at Oncoceutics, will present a talk titled “Activity of the Selective DRD2 Antagonist ONC201 in Recurrent Glioblastoma” at the Brain Tumor Biotech Summit 2017 at Lenox Hill Hospital in New York on June 2nd. The full agenda can be found here.

    • MAY 18 2017

    ONC201 Abstracts to be Presented at ASCO 2017

    Abstracts describing the recent clinical experience of ONC201 across various solid tumors will be presented at the 2017 American Society of Clinical Oncology (ASCO) annual meeting. The first, “Clinical activity of the selective DRD2 antagonist ONC201, an imipridone, in metastatic endometrial cancer (mEC)” will be presented in the session Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics

    • FEB 15 2017

    Dr. Josh Allen Presents Webinar on GPCRs With DiscoverX

    Recently, Oncoceutics’ VP of Research and Development Dr. Joshua Allen presented at a webinar hosted by DiscoverX, a leader in GPCR screening. G protein-coupled receptors (GPCRs) are the most commonly exploited drug target in modern medicine. These complex transmembrane receptors control several signaling pathways that are critical for cancer cells and are frequently hijacked by

    • APR 05 2016

    Presentations on ONC201 and Analogs at the 2016 AACR Annual Meeting

    Oncoceutics, Inc. announces that multiple abstracts will be presented on its lead compound, ONC201, and its analogs at the 2016 annual meeting of the American Association of Cancer Research (AACR) in New Orleans. Structure-activity relationships and mechanistic analysis of analogues of the clinical-stage anti-cancer small molecule ONC201 Presenter: Jessica Wagner Session time & date: Sunday, April 17th, 2016